// App-Quantinova.ai

10001 : Safety and Efficacy of Once Daily 220 mg Dabigatran Etexilate in a Real-World NonInterventional Study of More Than 5000 Patients After Total Knee or Hip Replacement

Researchers

Presenter

  • Charles Marc Samama

Principal Investigators

  • Martin Feuring

  • Eva Kleine

  • Satu Salmio

  • Andreas Clemens

  • Simon Frostick

Medical Centers

  • Bichat Univ Hosp, Paris, France

  • Faculty of Health & Life Sciences, Inst of Translational Med, Univ of Liverpool, Liverpool, United Kingdom

  • Hopital Cochin, Paris, France

Locations

  • France

  • United Kingdom

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Coronary Artery Disease

  • Venous thrombosis

  • Deep vein thrombosis

  • Pulmonary embolism

  • Congestive heart failure

Biomarkers

  • Transketolase Like 1

Drug/Treatment

  • Pradax

  • Enoxaparin

  • Enoxaparin sodium

Outcome

  • N/A

Study Design

  • observational

  • non interventional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved